Why CSL (ASX:CSL) Is Up 9.8% After Cutting FY26 Guidance On Impairments And Channel Shifts

• CSL has recently cut its FY26 revenue and profit forecasts following earnings downgrades, writedowns and impairments tied to shifts in US immunoglobulin sales channels and softer China albumin prices, ahead of its full-year results and dividend announcement previously scheduled for 18 August 2026.
• Despite these setbacks, investors appear increasingly focused on CSL’s turnaround prospects and the possibility that future impairments could be more contained than previously feared.
• We’ll now examine how renewed investor optimism around a potential operational turnaround, despite recent downgrades and impairments, reshapes CSL’s investment narrative.

Find 6 companies with promising cash flow potential yet trading below their fair value.

CSL Investment Narrative Recap

To stay invested in CSL today, you need to believe the core plasma and specialty medicines business can absorb channel shifts in US immunoglobulin and softer China albumin pricing, while management stabilises earnings after the FY26 guidance cut. The near term catalyst is the 18 August 2026 full year result and dividend update, where clarity on revenue trends and further impairments will be critical. The biggest risk right now is that write downs and US channel disruption prove larger or longer lasting than expected.

Against this backdrop, CSL’s FY26 revenue guidance of about US$15.2 billion, issued on 10 May 2026, is central to the story. It already reflects a reduction versus earlier expectations and sits uncomfortably beside recent impairments and margin pressure. How management updates this outlook at the full year result, particularly in light of weaker China albumin pricing and US immunoglobulin channel changes, will frame how credible any turnaround narrative looks to investors.

Yet behind the renewed optimism, investors should be aware of the risk that further impairments and margin pressure from plasma and albumin markets could...

Read the full narrative on CSL (it's free!)

CSL’s narrative projects $16.9 billion revenue and $3.3 billion earnings by 2029.

Uncover how CSL's forecasts yield a A$140.86 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Before the latest downgrade, the most optimistic analysts were pencilling in about US$18.4 billion of revenue and US$4.4 billion of earnings by 2029, which is a far more upbeat story than today’s guidance implies. If you compare that to the current focus on cost cuts and restructuring risk, you can see how far expectations can stretch, and why it is worth exploring several contrasting views on CSL’s future.

Explore 12 other fair value estimates on CSL - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CSL research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free CSL research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CSL's overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 9 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com